Compare GOAI & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GOAI | SERA |
|---|---|---|
| Founded | 2015 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Precision Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 89.9M | 75.2M |
| IPO Year | 2023 | 2021 |
| Metric | GOAI | SERA |
|---|---|---|
| Price | $1.66 | $1.98 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 195.5K | 36.4K |
| Earning Date | 04-10-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 966.67 | 32.32 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $17,037,328.00 | $81,000.00 |
| Revenue This Year | N/A | $554.81 |
| Revenue Next Year | N/A | $517.27 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 82.59 | 5.19 |
| 52 Week Low | $1.42 | $1.56 |
| 52 Week High | $6.67 | $3.95 |
| Indicator | GOAI | SERA |
|---|---|---|
| Relative Strength Index (RSI) | 30.63 | 48.26 |
| Support Level | N/A | $1.88 |
| Resistance Level | $2.68 | $2.12 |
| Average True Range (ATR) | 0.16 | 0.15 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 37.10 | 42.63 |
Eva Live Inc is a United States-based technology company that has developed an automated and intelligent advertiser campaign management platform, Eva Platform, which enables advertisers ('customers, clients') to buy advertising space on several digital channels to reach their desired audience. The company also works with Businesses that utilize its in-house digital marketing capabilities, including advice, creative services, account management, production of advertising materials, media planning, and buying.
Sera Prognostics Inc is a health diagnostic company. It is a women's health company utilizing the proprietary proteomics and bioinformatics platform, and data resources to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.